Independent
Tenure on this board
11.1 yrs
Also a director at
Rhythm Pharmaceuticals Inc (RYTM)Alumis Inc (ALMS)
Meeting calendar
NEO · Annual meeting · Thursday, May 21, 2026
Neogenomics Inc
9 nominees · 4 ballot items.
Election of nine directors; advisory approval of executive compensation (say-on-pay); approval of Second Amendment to the 2023 Equity Incentive Plan to increase share reserve by 5,000,000; and ratification of Deloitte & Touche LLP as independent auditor.
Market cap
$1.9B
1Y TSR
+101.4%
Board grade
C+
Record date
Mar 23, 2026
Filing
DEF 14A
Meeting concluded · May 21, 2026
Follow how the vote landed and what changed on Neogenomics Inc’s board — director track records, governance grades, and ongoing monitoring — on the Boardroom Alpha platform.
Proposals
On the ballot4
- 1
Election of Directors
ManagementBoard: FORElect nine director nominees to serve until the next annual meeting.
- 2
Advisory Vote on Executive Compensation
ManagementBoard: FORNon-binding, advisory approval of compensation paid to the named executive officers (say-on-pay).
- 3
Second Amendment of the 2023 Equity Incentive Plan
ManagementBoard: FORApprove amendment to increase the number of shares reserved under the 2023 Equity Incentive Plan by 5,000,000 shares (from 8,300,000 to 13,300,000).
- 4
Ratification of Appointment of Independent Registered Public Accounting Firm
ManagementBoard: FORRatify the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for fiscal 2026.
Director elections
Nominees on the ballot9
Independent
Tenure on this board
1.1 yrs
Independent
Tenure on this board
3.1 yrs
Independent
Tenure on this board
9.0 yrs
Independent
Tenure on this board
6.0 yrs
Also a director at
Dmc Global Inc (BOOM)Prime Medicine Inc (PRME)
Independent
Tenure on this board
0.5 yrs
Also a director at
Quantum-si Inc (QSI)Orasure Technologies Inc (OSUR)
Independent
Tenure on this board
3.7 yrs
Independent
Tenure on this board
1.7 yrs
Not independent
Tenure on this board
3.1 yrs
Also a director at
NONE
Ownership
Latest 13F quarterTop institutional holders10
| # | Owner | % of shares | Shares | Value |
|---|---|---|---|---|
| 1 | BlackRock, Inc. | 10.6% | 13,843,489 | $103M |
| 2 | First Light Asset Management, LLC | 7.5% | 9,729,978 | $72M |
| 3 | Greenhouse Funds LLLP | 7.0% | 9,100,103 | $68M |
| 4 | VANGUARD PORTFOLIO MANAGEMENT LLC | 5.9% | 7,622,187 | $57M |
| 5 | FIRST TRUST ADVISORS LP | 4.7% | 6,162,371 | $46M |
| 6 | VANGUARD CAPITAL MANAGEMENT LLC | 4.3% | 5,655,823 | $42M |
| 7 | BRAIDWELL LP | 4.3% | 5,617,402 | $42M |
| 8 | STATE STREET CORP | 3.9% | 5,119,838 | $38M |
| 9 | BlackRock, Inc. | 3.1% | 4,084,688 | $30M |
| 10 | SCHRODER INVESTMENT MANAGEMENT GROUP | 2.7% | 3,568,578 | $26M |
Peers
Nearest market capOther Healthcare sector meetings6
Upcoming shareholder meetings at Neogenomics Inc’s closest sector peers — compare boards, ballots, and ownership across the cohort.
Trulieve Cannabis CorpTRLV
Special meeting·Aug 5, 2026·$1.6B
Anaptysbio IncANAB
Annual meeting·Aug 11, 2026·$1.6B
Prestige Consumer Healthcare IncPBH
Annual meeting·Aug 4, 2026·$2.4B
Avanos Medical IncAVNS
Special meeting·Jul 22, 2026·$1.2B
Aura Biosciences IncAURA
Special meeting·Aug 5, 2026·$712M
Organon & CoOGN
Special meeting·Jul 23, 2026·$3.5B
Reference
Frequently asked questions
- When is the Neogenomics Inc 2026 annual meeting?
- Neogenomics Inc (NEO) holds its 2026 annual shareholder meeting on Thursday, May 21, 2026.
- What is the record date for the Neogenomics Inc 2026 meeting?
- The record date for the Neogenomics Inc 2026 meeting is Monday, March 23, 2026. Shareholders of record on or before that date are eligible to vote.
- Who are the director nominees for Neogenomics Inc's 2026 meeting?
- The board is presenting 9 director nominees at the Neogenomics Inc 2026 meeting, listed with their independence status and background.
- What proposals will shareholders vote on at the Neogenomics Inc 2026 meeting?
- Shareholders will vote on 4 proposals at the Neogenomics Inc 2026 meeting, each tagged with who proposed it and the board's recommendation.
Disclaimer
The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.
This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.
None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.